Gedeon Richter Plc., headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe, in China and in Latin America. Headquarter is located in Budapest (Hungary). Having reached a market capitalization of EUR 3.9 billion (USD 4.1 billion) by the end of 2022, Richter’s consolidated sales were approximately EUR 2 billion (USD 2.1 billion) during the same year. The product portfolio of company covers many important therapeutic areas, including Women’s Healthcare, Central Nervous System and Cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter’s original research activity focuses on CNS disorders. With its widely acknowledged steroid production expertise, Richter is a significant player in the Women’s Healthcare field worldwide. Richter is also active in biosimilar product development.
Gedeon Richter has 8 manufacturing and research facilities all over the world as well as its own plant in Russia. It was opened more than 25 years ago and became the first Gedeon Richter’ foreign site in this country. Gedeon Richter is a socially responsible company, implementing CSR projects both at the global and Russian levels. The project “Richter’s Women’s Health Week” is an outstanding example of the company’s contribution to building a culture of self-care and care about reproductive health in Russian women. Today, the company employs more than 12,000 people in the world, including about 1,400 who work in Russia.
According to IQVIA, in 2022 Gedeon Richter is among the TOP 15 companies in the pharmaceutical retail market in ruble terms. According to the results of the annual rating of the newspaper Farmacevticheskiy vestnik, in 2022 Gedeon Richter is included in the TOP 10 most influential foreign manufacturers